AstraZeneca's Fredrickson On Its Cancer Ambitions
Just over a year ago, AstraZeneca at last returned to growth and set about a reorganization that placed oncology at the heart of its plans for continued success. In Vivo talked to the executive vice-president of its Oncology Business Unit David Fredrickson about how the company hopes to become a major cancer player.
You may also be interested in...
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.
The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.
Insmed shares got a 40% boost as the company announced plans to move into Phase III this year with its potential first-in-class candidate for the lung disease.